An evaluation of the policy of routine treatment of advanced epithelial ovarian carcinoma by debulking surgery and combined platinum-cyclophosphamide chemotherapy in Singapore

International Journal of Gynecological Cancer

Volumn 6, Issue 1, 1996, Pages 44-48

  Tay, S K ^a   Chang, T C ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

5 year survival; cisplatin; neutropenia; ovarian cancer; thrombocytopenia

Indexed keywords

CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; PLATINUM;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NEUROPATHY; OVARY CARCINOMA; PRIORITY JOURNAL; SEPSIS; SINGAPORE; TREATMENT OUTCOME;

EID: 0029869282     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06010044.x     Document Type: Article

References (18)

1. Silverberg E, Lubera JA. Cancer statistics. Cancer 1989; 39: 3-20.
2. Annual report of the results of treatment in gynecological cancer. 21st Volume. Int J Obstet Gynecol 1991; 36: 238-57.
3. Sondik EJ, Young JL, Horm JW, Gloeckler LA. Annual Cancer Statistics Review. NIH Publications, 1985; 86-2789.
4. Neijt JP. Treatment of advanced ovarian cancer: 10 years of experience. Ann Oncol 1992; 3: 17-27.
5. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. Br Med J 1991; 303: 884-93.
6. Omura GA, Buyse M, Marsoni S, et al. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a metaanalysis. J Clin Oncol 1991; 4: 1668-74.
7. Kaye SB, Lewis CR, Duncan ID, et al. Randomised study of 2 doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-33.
8. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in Stage I and Stage II epithelial ovarian cancer. N Engl J Med 1990; 322: 1021-7.
9. Gershenson DM, Copeland LJ, Wharton JT, et al. Prognosis of surgically determined complete responders in cancer. Cancer 1985; 55: 1129-35.
10. Baak JPA, Wisse-Brekelmans ECM, Langley FA, Talerman A. Morphometric data to FIGO Stage and histologic type and grade of prognosis of ovarian tumours. J Clin Pathol 1986; 39: 1340-6.
11. Swenerton K, Fraser R, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer. A randomised phase III study of the National Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10: 718-26.
12. Hand R, Fremgen A, Chmiel JS, et al. Staging procedures, clinical management and survival outcome for ovarian carcinoma. J Am Med Assoc 1993; 269: 1119-24.
13. Ozols R, Young R. Chemotherapy of ovarian cancer. Sem Oncol 1984; 11: 251-65.
14. Vogl S, Pagano M, Kaplan B, Greenwald E, Arseneau J, Bennett B. Cisplatin based combination chemotherapy for advanced ovarian cancer: High overall response rate with curative potential only in women with small tumour burdens. Cancer 1983; 51: 2024-30
15. Gruppo Interegionale Cooperative Oncologico Ginecologia. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/ cisplatin in advanced ovarian cancer. Lancet 1987; ii: 353-9.
16. Wiltshaw E, Evans B, Rustin G, Gilbey E, Baker J, Barker G. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 1986; 4: 722-9.
17. Levin L, Hryniuk W. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756-67.
18. Bronchud MH, Howell A, Crowther D, Hopwood P, Souza L, Dexter TM. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989; 60: 121-5.